In memory of Jason Christiansen, Ph.D., who served as the Chief Technology Officer of Epic Sciences. Jason was an instrumental leader in the launch of DefineMBC, a novel liquid biopsy test to improve care for patients battling metastatic breast cancer. For more than 20 years he dedicated his career to research & development work that advanced healthcare and personalized medicine. We honor his commitment to improving the lives of patients and we will continue the work of advancing care for patients with cancer.

Amara Siva, Ph.D. joined Epic Sciences as the Vice President of Lab Operations in 2021.  Dr. Siva has over 20 years of molecular diagnostic development experience, including assay development from concept stage to clinical validation, and the launch and scaling of molecular and immunologic diagnostic tests into commercial clinical laboratories as well as implementation into global clinical trials. Prior to joining Epic Sciences, Dr. Siva served in leadership roles in CLIA laboratory operations management, clinical trials, and research at companies including Pathnostics, Millennium Health, Genoptix/Novartis, Gen-Probe, and Alexion. Dr. Siva received her B.S. in Biochemistry and Cell Biology from UC San Diego and Ph.D. in Biological Chemistry from UCLA. She is an ASQ-certified Six Sigma Green Belt, holds a Clinical Genetic Molecular Biologist Scientist license in the State of California, and is certified as a High-complexity Clinical Laboratory Director by the American Board of Bioanalysis.

As Vice President, Product Strategy, Ms. Tubbs has over 20 years of broad industry experience successfully developing technology solutions as well as bringing global products to market. Her expertise driving strategy in the diagnostic space spans from concept creation to address unmet medical needs through clinical evidence build and market access. She has established collaboration and program management teams and processes within top Pharmaceutical companies such as Roche and AstraZeneca and is committed to improving cancer patient care through innovation.

Eva Wang, Ph.D. joins Epic Sciences with more than 15 years of industrial and academic experience focused on the intersection of computer science, biology, machine learning, and statistics spanning biomedical research, molecular diagnostics, and therapeutics. Before Epic Sciences, Dr. Wang held various leadership positions with responsibilities spanning from dry lab to R&D and Operations at four successful biotech startup companies, one of which was acquired and three completed IPOs. She recently served at the Gladstone Institutes, where she led a team of cross-disciplinary scientists and engineers to bring cutting edge technology to the Gladstone scientific community. Dr. Wang holds a BS in Microbiology, Ph.D. in computer science from UC Santa Cruz, and an MBA from the Wharton School.

Martin Blankfard joined Epic Sciences as the Vice President of Strategic Initiatives in 2019.  Martin has over 30 years of platform development experience in both veterinary and IVD clinical diagnostics across startup, mid-size, and large companies.  He has in-depth knowledge in multiple immunoassay diagnostic platforms including ELISA, IHC, Electro-Chemi and Chemiluminescent, lateral flow, flow cytometry, Luminex, and many forms of cell-based technologies.  During his 30-year tenure Martin has led R&D, product management, business development, and operations.  Martin holds a B.S. Degree in Food Science and a Master of Science Degree in Physiology from the University of Maryland.

Peter Kuhn, PhD, is Founder and Chief Scientific Advisor at Epic Sciences. He is the principal architect of the Epic Sciences platform and has invested his career into the research, development, and the clinical utility of the liquid biopsy. His vision of translating innovation in research to meaningful products for patient care is driving his everyday efforts.

Dr. Kuhn is the Dean’s Professor of Biological Sciences, Professor of Medicine, Aerospace & Mechanical Engineering, and Biomedical Engineering at the University of Southern California. He also serves as the Director of the USC Michelson Convergent Science Institute in Cancer (CSI-Cancer) and the deputy director of the Convergent Science – Virtual Cancer Center. He holds a chair as Honorary Professor of Cancer Science at the University of Manchester in the United Kingdom.

Previously, Dr. Kuhn held faculty appointments at The Scripps Research Institute and at Stanford University. While at Stanford, Dr. Kuhn established the structural genomics research enterprise and focused his research on technology developments in structural biology that were utilized by breakthrough research such as Dr. Roger Kornberg’s (Nobel prize 2006) structure determination of the RNA Polymerase. Dr. Kuhn joined Scripps and advanced technologies that led to the structure determination of the human b2AR GPCR with collaborators including Dr. Brian Kobilka (Nobel prize 2012).

Dr. Kuhn is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 including research with Drs. Michael Radermacher and Joachim Frank (Nobel prize 2017) in electron microscopy and his Ph.D. in 1995 with Dr. Patrick VanRoey in X-ray crystallography. He then moved to Stanford University where he joined the faculties of Medicine and Accelerator Physics as tenure track Assistant Professor. From 2002 to 2014 he established the Physics Oncology program at The Scripps Research in La Jolla, CA as tenured Associate Professor before joining USC in 2014. His research and inventions have resulted in over 300 peer-reviewed publications, which have been cited over twenty-thousand times.

Richard J. Wenstrup, MD joins Epic Sciences as Chief Medical Officer, bringing more than 25 years of clinical leadership experience managing life science companies before joining industry from academia.

Dr. Wenstrup was previously chief medical officer for Oxford Immunotec, Inc., where he oversaw research and development, product development, regulatory, medical and clinical affairs. From 2006-2017, he served as chief medical officer for Myriad Genetics, where he built and led the clinical and medical affairs team to support a multi-fold increase in revenue during his tenure. Dr. Wenstrup was actively involved in the company’s product development, M&A and in-licensing activities.‍

Prior to joining industry, Dr. Wenstrup served as a tenured professor of pediatrics in human genetics at Cincinnati Children’s Hospital Medical Center and as a tenured professor of biomedical engineering at the University of Cincinnati, where he earned his medical degree. He was internationally recognized as a leader in inherited disorders of the musculoskeletal system and was principal investigator on multiple research grants from the National Institutes of Health and the FDA Orphan Products Grant Program. As an entrepreneur, Dr. Wenstrup was the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children’s Hospital and co-founder of Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc.

Lloyd Sanders joined Epic Sciences as President and Chief Executive Officer in 2019 with more than 20 years of diagnostics and pharmaceutical industry experience, most of it focused on oncology. Prior to joining Epic, he served as president of the oncology segment of Myriad Genetics, overseeing the oncology, urology and dermatology commercial organizations. While at Myriad, he was responsible for the sales, marketing, medical, customer service and laboratory operations for numerous market-leading commercial products, including molecular diagnostics for risk assessment, diagnosis/screening, prognosis and selection of therapies for breast, prostate, colorectal and other cancers.

Previously, Mr. Sanders served as chief operating officer at Dey Pharma, a division of Mylan, overseeing sales, marketing and medical affairs, including the EpiPen® flagship brand. Prior to Dey Pharma, he held several leadership positions including responsibility for the commercial growth of a number of oncology products at Sanofi-Synthelabo, subsequently Sanofi-Aventis, where he led the successful restructuring and integration of two companies’ sales forces after the merger. Mr. Sanders started his pharmaceutical career and participated in oncology product launches at Pharmacia (now Pfizer).

Mr. Sanders earned a Bachelor’s business degree with an emphasis in marketing from Memphis State University.

Joel Smith serves as General Counsel, Chief Compliance Officer, and Executive Vice President, Corporate Development at Epic Sciences.

A veteran legal professional with more than 20 years of experience in the life sciences and biopharmaceutical industries, Mr. Smith brings a breadth of knowledge in strategic corporate development, complex commercial transactions, licensing, securities law, corporate governance and regulatory compliance. Smith has served as a senior executive and general counsel for a number of biotechnology and life sciences companies, including BioQ, Triad Therapeutics, and Sientra, Inc. At Sientra, Smith was responsible for all of its legal affairs including corporate compliance, commercialization policies, and intellectual property. He was a primary contributor to its premarket application for FDA approval of its implants and in the preparation of the prospectus used in its initial public offering on Nasdaq.

Most recently, Smith was the managing counsel of Qualcomm Life, the medical device subsidiary of Qualcomm where he and his team supported global sales and business development teams.

Smith earned his Juris Doctorate, cum laude, and a Master of Business Administration, with highest distinction, from the University of Michigan, as well as a Bachelor of Science in Cellular and Molecular Biology and Economics. He is a member of the State Bar of California.